GlassScriptPhysician profile
Vinay Raja
NPI 1386677938
$30,119.57
in general payments reported to CMS, 2019-2025
19 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,598 · 2020: $4,125 · 2021: $3,946 · 2022: $1,200 · 2023: $7,656 · 2024: $4,820 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,208 · Food and Beverage: $493 · Education: $205 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,145.50 |
| Travel and Lodging | $1,207.78 |
| Food and Beverage | $492.98 |
| Education | $204.70 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $12,056.55 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $9,291.74 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Athenex Pharmaceutical Division, LLC | $4,025.00 | 2020 | |
| Daiichi Sankyo INC. | $1,400.00 | 2022-2025 | Vanflyta |
| Lilly USA, LLC | $1,074.37 | 2021-2023 | Retevmo |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Emd Serono, INC. | $500.00 | 2021 | |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Abbvie INC. | $190.35 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $30.22 | 2022-2025 | Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $24.35 | 2024 | Ojjaara |
| Sobi, INC | $24.04 | 2024 | |
| Pfizer INC. | $16.60 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.83 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.